Purchase Order 75N91022P00578
Award Date
7/6/22
Potential Completion Date
7/5/24
Potential Value
$82K
Federal Agency
National Cancer Institute
Awardee
Illumina, Inc.
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Competed under SAP
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Bethesda, MD 20892, USA
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This firm fixed price purchase order contract was awarded by the National Cancer Institute (NCI), part of the National Institutes of Health (NIH) under the U.S. Department of Health and Human Services (HHS), to Illumina, Inc., a leading manufacturer of genetic sequencing and genomic analysis technologies. The $235,228 contract provides for preventive maintenance, emergency service, and support for a government-owned Illumina NextSeq 2000 sequencing system used in support of the NCI's research...
This is a federal contract award to Illumina, Inc., a manufacturer of sequencing and array-based solutions for genetic and genomic analysis. The contract, valued at $149,627.88, was awarded by the National Human Genome Research Institute (NHGRI), which is part of the National Institutes of Health (NIH), a civilian agency. The contract is a delivery order and is a firm fixed-price arrangement, with no set-aside designation. Illumina has previously provided a range of sequencing systems, reagents,...
This federal contract award to Illumina, Inc. was issued by the National Human Genome Research Institute (NHGRI), part of the National Institutes of Health (NIH). The $159,746.65 firm fixed price delivery order contract is for the provision of Illumina's proprietary sequencing systems, reagents, consumables, and related services to support genomic sequencing and analysis. This appears to be a follow-on to previous prime contracts Illumina has held with various federal agencies for similar...
This federal contract award is for the procurement of an Illumina NextSeq 2000 sequencing system by the National Cancer Institute, which is part of the National Institutes of Health (NIH) under the Department of Health and Human Services (HHS). The award, valued at $239,190.00, was issued on a firm fixed price basis to Illumina, Inc., a for-profit manufacturer of genetic and genomic analysis instruments and reagents. The contract did not have a set-aside designation. This award appears to be...
The Department of Health and Human Services National Institutes of Health National Cancer Institute awarded a firm fixed price purchase order contract valued at $300,280.00 to Illumina, Inc. for maintenance services on Illumina NextSeq 500 genomic sequencing equipment. The contract has a completion date of May 18, 2023 and was awarded on May 19, 2018. Illumina, a for-profit manufacturer of genomic analysis instruments and reagents, has been awarded numerous prime and subcontract federal awards...
This firm fixed-price purchase order was awarded by the National Institute of Environmental Health Sciences (NIEHS), a civilian agency within the U.S. government, to Illumina, Inc., a leading manufacturer of genetic sequencing technologies. The $62,395.00 contract is for the maintenance and service of two Illumina NextSeq and MiSeq sequencing instruments used by NIEHS. The award does not utilize any set-aside designations. Illumina has been awarded multiple federal contracts and grants by...
This is a $114,198.14 firm fixed price purchase order awarded by the National Cancer Institute (NCI), a component of the National Institutes of Health (NIH), to Illumina, Inc. for their NextSeq 550 comprehensive service plan. The contract is not set aside and has an ultimate completion date of July 31, 2024. Illumina is a manufacturer of sequencing and array-based solutions for genetic and genomic analysis, and has previously received prime federal contracts and subcontracts from agencies...
This $141,890.61 federal contract was awarded by the Department of Health and Human Services' National Institutes of Health (NIH) National Cancer Institute to Illumina, Inc., a manufacturer of genomic sequencing instruments and consumables. The contract is for the delivery of reagents and consumables, with a firm fixed price and no set-aside designation. Illumina has previously provided sequencing systems, reagents, and services to support genomic research and diagnostics across various...
This federal contract award, valued at $99,813.12, was issued by the National Institute of Environmental Health Sciences to Illumina, Inc., a manufacturer of genomic sequencing and analysis instruments and reagents. The award is for the delivery of Illumina's sequencing systems, including the NextSeq, NovaSeq, MiSeq, and iSeq platforms, along with accompanying reagents, consumables, and support services. This contract is not subject to any set-aside requirements. Illumina has previously received...
This is a firm fixed price delivery order contract awarded by the National Cancer Institute, a civilian agency within the Department of Health and Human Services, to Illumina, Inc., a for-profit manufacturer of genetic analysis instruments and reagents. The contract, valued at $81,640.80, is for the provision of NEXTSEQ 500/500 sequencing systems and related catalog items. The award has no set-aside designation. Illumina has previously provided sequencing systems and services to support...